Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
07:05am, Tuesday, 04'th Nov 2025
Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
07:00am, Tuesday, 04'th Nov 2025
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potent
Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 82.93%: Here's is How to Trade
10:56am, Thursday, 30'th Oct 2025
The consensus price target hints at an 82.9% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Brokerages
02:36am, Sunday, 26'th Oct 2025
Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve research firms that are covering the firm, MarketBeat reports. One r
Ocular Therapeutix (OCUL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:56am, Friday, 24'th Oct 2025
After losing some value lately, a hammer chart pattern has been formed for Ocular Therapeutix (OCUL), indicating that the stock has found support. This, combined with an upward trend in earnings estim
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
07:00am, Tuesday, 07'th Oct 2025
BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today an
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
04:22am, Wednesday, 01'st Oct 2025
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Analyst/Investor Day September 30, 2025 2:00 PM EDT Company Participants Pravin Dugel - Executive Chairman, President & CEO Nadia Waheed - Chief Medical Officer
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
07:08am, Tuesday, 30'th Sep 2025
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina
SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026
Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
05:05pm, Monday, 08'th Sep 2025
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Pravin Dugel - Executive Chairman, President & CEO Pr
Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care
01:52am, Sunday, 07'th Sep 2025
Ocular Therapeutix's value hinges on Axpaxli's Phase 3 success in Wet AMD, with recent protocol changes signaling management's confidence and bullish prospects. The company is well-capitalized through
OCUL Sales Drop 18%
09:12pm, Tuesday, 05'th Aug 2025
Ocular Therapeutix (OCUL -2.83%), a biotechnology company developing therapies for eye diseases, reported its second quarter results on August 5, 2025. The earnings release pointed to a significant wi
Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript
01:33pm, Tuesday, 05'th Aug 2025
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants Pravin U. Dugel - Executive Chairman, President & CEO William S.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
09:25am, Tuesday, 05'th Aug 2025
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.24 per share a year ago.
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
07:00am, Tuesday, 22'nd Jul 2025
BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced part
